检索结果-南通市图书馆

World Journal of Clinical Cases 2024年第34期12卷 6721-6727页

作者： Yu Igata Masashi Kudo Motohiro Kojima Shota Kami Keishiro Aoki Tomoyuki Satake Tatsushi Kobayashi Motokazu Sugimoto Shin Kobayashi Masaru Konishi Naoto Gotohda Department of Hepatobiliary and Pancreatic surgery National Cancer Center Hospital EastKashiwa 277-8577Japan Exploratory Oncology Research and Clinical Trial Center National Cancer CenterKashiwa 277-8577Japan Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital EastKashiwa 277-8577Japan Department of Diagnostic Radiology National Cancer Center Hospital EastChiba 277-8577Japan

BACKGROUND The combination of immune checkpoint inhibitors and chemotherapy has shown promising results for the treatment of advanced biliary tract cancer(BTC).Based on the results of the TOPAZ-1 trial,a gemcitabine and cisplatin plus durvalumab(GCD)regimen was recently approved as first-line therapy for patients with advanced ***,post-GCD conversion surgery has not been previously ***,we describe a case of advanced intrahepatic cholangiocarcinoma(ICC)successfully treated with radical surgery after *** SUMMARY A 65-year-old female diagnosed with advanced ICC with periductal infiltration into the hepatic hilum underwent eight cycles of GCD,followed by durvalumab maintenance treatment,with mild adverse *** response was ***,a conversion surgery with extended left hepatectomy and bile duct resection was *** resection margins were negative,and the pathological diagnosis was compatible with small duct type *** patient remained disease-free for 8 months without adjuvant *** We describe the case of a patient who received successful conversion surgery after GCD treatment for advanced ICC.

关键词： conversion surgery Intrahepatic cholangiocarcinoma Small duct type Immunotherapy Case report

conversion surgery for stage Ⅳ gastric cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Metastasis and Treatment 2018年第1期4卷 272-280页

作者： Satoshi Ida Masayuki Watanabe Department of Gastroenterological surgery Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyo 135-8550Japan

Gastric cancer with distant metastases,such as para-aortic lymph node metastases,hepatic metastases,and peritoneal dissemination,is classified as stage *** this situation,cancer cells have formed micrometastases throughout the body;therefore,according to the algorithm of the Japanese guidelines,stage IV cancer is outside the indication for curative *** advances in some chemical agents have been remarkable,and some patients have survived for long periods even with stage IV gastric ***,even in patients with stage IV gastric cancer,there is a possibility that gastrectomy as conversion surgery could play an important role in the treatment *** as conversion therapy can be safely conducted without perioperative mortality and is considered a sufficiently acceptable treatment ***,the significance of conversion surgery for stage IV gastric cancer remains *** this review,we summarize the treatment strategies and outcomes of conversion surgery for stage IV gastric cancer.

关键词： Gastric cancer stageⅣ gastrectomy conversion surgery outcome

conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma: where do we stand in 2018?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Pancreatology 2018年第1期1卷 25-29页

作者： Sohei Satoi Tomohisa Yamamoto Yoichi Matsui Department of surgery Kansai Medical UniversityHirakataJapan

Pancreatic ductal adenocarcinoma(PDAC)continues to have a dismal prognosis,with a 5-year survival rate of<5%.Most(70%-80%)patients are classified as unresectable(UR)*** progress in chemotherapeutic approaches has prov... 详细信息

Pancreatic ductal adenocarcinoma(PDAC)continues to have a dismal prognosis,with a 5-year survival rate ofconversion surgery(CS),which is defined as an additional surgery during multimodal therapy in patients with initially UR-PDAC who respond favorably to anti-cancer treatments,has been successfully introduced as a novel treatment option for locally advanced(UR-LA)and metastatic(UR-M)*** studies have demonstrated high resectability rates(UR-LA,20%-57%;UR-M,2%-24%),high margin-negative resection rates(27%-91%),and high negative lymph node rates(29%-83%)in patients who underwent *** studies also demonstrated acceptable mortality and *** survival time(MST)varied between 24.9 and 35.3 months for patients with UR-LA,19.5 and 64 months for UR-LA/M,and 26 and 56 months for UR-M,which is better than the MST of patients who did not undergo *** presence of M disease did not affect survival in patients who underwent ***,the actual clinical benefits of resection have not yet been fully *** are still several issues to be resolved in this ***,sustained efforts to conduct appropriately designed clinical trials for confirming the efficacy of CS in the subset of patients with initially UR-PDAC are warranted.

关键词： conversion surgery Distant organ metastasis Locally advanced Tumor marker Unresectable pancreatic ductal adenocarcinoma

Survival outcomes of conversion surgery for metastatic pancreatic ductal adenocarcinoma after neoadjuvant therapy

维普期刊数据库

同方期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Pancreatology 2023年第3期6卷 110-118页

作者： Lingyu Zhu Suizhi Gao Xinqian Wu Bo Li Xiaohan Shi Xiaoyi Yin Huan Wang Meilong Shi Penghao Li Yikai Li Chaoliang Zhong Chuanqi Teng Jiawei Han Yiwei Ren Jian Wang Zhendong Fua Xinyu Liu Kailian Zheng Shiwei Guo Gang Jin Department of Pancreatic Hepatobiliary surgery Changhai HospitalNaval Medical UniversityYangpu DistrictShanghaiChina

Objective:To evaluate the survival outcomes of patients who underwent conversion surgery for metastatic pancreatic ductal adenocarcinoma(mPDAC)after neoadjuvant therapy(NAT)and to identify potential candidates that may benefit from this treat-ment ***:The role and eligibility population of conversion surgery for mPDAC remains controversial in the era of ***:A consecutive cohort of patients diagnosed with mPDAC and treated with NAT followed by conversion surgery be-tween 2019 and 2021 were confirmed from a prospective database maintained by the Department of Pancreatic Hepatobiliary surgery of Changhai *** accordance with residual metastases and technical resectability after NAT,patients were classi-fied as the complete pathological response of metastases(ypM0)resection group,residual metastases(ypM1)resection group,and exploration *** overall survival(mOS)was calculated using the Kaplan-Meier method,uni-and multivariable cox regression was performed to identify clinicopathological predictors of ***:A total of 244 patients with mPDAC were identified from the prospective database,with 19(7.8%)patients who un-derwent ypM0 resection,22(9.0%)underwent ypM1 resection,and 23(9.4%)underwent explorative *** mOS was 32.6 months for ypM0 resected patients,15.1 months for ypM1 resected patients,and 13.4 months for those who underwent explorative laparotomy(Pconversion surgery for mPDAC after *** analyses revealed that oligometastases and continued adjuvant therapy were associated with improved prognosis in the ypM1 resection ***:In patients with mPDAC who underwent NAT followed by conversion surgery,the complete pathological response of metastases,normalization of preoperative CA19-9 levels,and c

关键词： conversion surgery Metastatic pancreatic ductal adenocarcinoma Neoadjuvant therapy Survival

HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum:A case report

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第28期27卷 4738-4745页

作者： Yoshifumi S Hirokawa Takashi Iwata Yoshinaga Okugawa Koji Tanaka Hiroyuki Sakurai Masatoshi Watanabe Department of Oncologic Pathology Mie University Graduate School of MedicineMie 5148507Japan Cancer Center Aichi Medical UniversityAichi 4801195Japan Department of Genomic Medicine Mie University HospitalMie 5148507Japan Department of surgery IGA City General HospitalMie 5180823Japan Hepato-biliary-pancreatic and Transplant surgery Mie University HospitalMie 5148507Japan

BACKGROUND Adenocarcinoma originating from heterotopic pancreas tissue is a rare ***,to our knowledge,no HER2-positive cases in the duodenum have been reported in the scientific literature nor has the efficacy of trastuzumab treatment for the disease been *** SUMMARY A 65-year-old woman whose clinical diagnosis was unresectable advanced duodenal cancer with HER2 overexpression responded well to trastuzumab *** main tumor in the duodenum reduced *** patient underwent pancreaticoduodenectomy and lymph node dissection.A small number of cancer cells remained in the submucosal layer of the duodenum and pancreas *** histological and immunohistochemical examination,the patient was diagnosed with duodenal adenocarcinoma originating from heterotopic pancreas *** Trastuzumab treatment is effective in HER2-positive adenocarcinoma originating from heterotopic pancreas tissue in the duodenum.

关键词： Heterotopic pancreas tissue Duodenal cancer Human epidermal growth factor receptor 2 Trastuzumab conversion surgery Case report

Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary surgery and Nutrition 2021年第4期10卷 434-442页

作者： Xiaobo Yang Haifeng Xu Bangyou Zuo Xu Yang Jin Bian Junyu Long Dongxu Wang Junwei Zhang Cong Ning Yanyu Wang Ziyu Xun Yunchao Wang Xin Lu Yilei Mao Xinting Sang Haitao Zhao Department of Liver surgery State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC)BeijingChina

Background:A combination of tyrosine kinase inhibitors(TKIs)and anti-PD-1 antibodies with local regional therapy has elicited yield substantial clinical benefits in patients who have hepatocellular carcinoma(HCC)with extrahepatic *** this treatment strategy to convert HCC patients with extrahepatic metastases from unresectable to resectable has not yet been ***:Consecutive hepatocellular carcinoma patients with extrahepatic metastases who received first-line therapy with a combination of TKIs and anti-PD-1 antibodies and at least one local regional therapy were ***:Nine patients with localized disease who received first-line systemic therapy were *** baseline,all of them had oligometastatic disease,namely,Barcelona Clinic Liver Cancer stage C(or Chinese Liver Cancer stage IIIB).The most common treatment administered was lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization,and the median time span from systemic therapy to surgery was 3.2(IQR,2.8-6.2)*** patients achieved a pathological complete *** patients underwent laparoscopic surgery,and the other 3 patients underwent open *** a median follow-up of 10.2(IQR,8.6-20.0)months,7 patients survived without disease recurrence,and 2 experienced tumour *** patients had any-grade AEs,and 55.6%of the patients experienced grade 3 *** was the most common AE,followed by elevated aminotransferase levels and ***:Stereotactic therapy is a feasible conversion therapy for HCC patients with extrahepatic metastases to become *** is the first study to analyse therapeutic outcomes of patients receiving these therapies for HCC with extrahepatic metastases.

关键词： Hepatocellular carcinoma(HCC) stereotactic therapy PD-1 systemic therapy conversion surgery

conversion therapy for hepatocellular carcinoma to improve treatment strategies for intermediate and advanced stages

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第28期12卷 6241-6243页

作者： Antonio Giorgio Massimo De Luca Athena Clinic Center Via MatesePiedimonte Matese(CE)81016CampaniaItaly Liver Unit AORN CardarelliVia A.CardarelliNapoli 80131CampaniaItaly

This manuscript is based on a case reported by Song et al published in the World Journal of Clinical *** challenges remain in the field of hepatocellular carcinoma(HCC)conversion ***,only a limited number of patients with HCC accompanied by portal vein tumor thrombosis(PVTT)and hepatic vein tumor thrombosis(HVTT)are eligible for *** clinical case demonstrates that considering the complexity of the disease,a multimodal and multidisciplinary approach is essential for managing HCC accompanied by PVTT and ***,the outcomes of such surgeries remain *** conclusion,research on HCC conversion therapy is extremely useful for impro-ving treatment strategies for intermediate and advanced HCC,which currently have disappointing clinical outcomes.

关键词： Hepatocellular carcinoma Portal vein Inferior vena cava Tumor thrombus conversion surgery